Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AZD4205 (Golidocitinib) in Healthy Adults
NCT03728023Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Nov 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in peripheral T-cell lymphoma (PTCL) comparing AZD4205 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal laboratory parameters and 2 more. Started Nov 2018; status: completed.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03728023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728023.